Modular tumor endoprostheses in surgical palliation of long-bone metastases: a reduction in tumor burden and a durable reconstruction

World Journal of Surgical Oncology

Jendrik Hardes¹  Gurpal Singh⁴  Steffen Hoell²  Tim Sauer³  Markus Nottrott¹  Arne Streitbuerger¹  Georg Gosheger¹  Juliane Krebs¹  Marcel-Philipp Henrichs¹ 

[1] Department of Orthopaedic Surgery, University Hospital Muenster, Albert-Schweitzer-Campus 1, Building A1, 48149 Muenster, Germany;Department of Orthopaedic Surgery, Paracelsus Hospital Osnabrueck, Am Natruper Holz 69, 49076 Osnabrueck, Germany;Department of Oncology, University Hospital Muenster, Albert-Schweitzer-Campus 1, Building A1, 48149 Muenster, Germany;University Orthopaedics, Hand and Reconstructive Microsurgery Cluster, National University Health System, Singapore, Singapore

关键词: Tumor endoprostheses;    Tumor burden;    Survival;    Surgical reconstruction;    Modular;    Bone metastasis;   

Others  :  1147534
DOI  :  10.1186/1477-7819-12-330

 received in 2014-03-29, accepted in 2014-10-20,  发布年份 2014

【 摘 要 】

Background

Surgical treatment of bone metastases has become increasingly important as patients live longer with metastatic cancer and one of the main aims is a long-lasting reconstruction which survives the patient. Conventional osteosynthesis may not be able to achieve this objective in the context of modern day cancer care.

Methods

This study evaluates the oncological outcomes, treatment-related complications, and function after resection of metastases and reconstruction with modular tumor endoprostheses in 80 patients. All patients who underwent surgical treatment with modular tumor prostheses for bone metastases from 1993 to 2008 were traced by our tumor database and clinical information was recorded from patient case.

Results

Mean age was 63 years. The most common primary tumors were renal cell (47%), breast (21%), and lung (8%). The proximal femur was affected in 45%, proximal humerus in 26%, and the distal femur in 17% of cases. In 22 cases, the tumor prosthesis was implanted during a revision operation. Mean overall survival after surgery was 2.9 years. Overall survival rate was 70% at one year and 20% at five years. Implant survival was 83% after one year and 74% at five years. Overall rate of operative revision was 18%.

Conclusions

Our data collectively suggest that despite higher costs, implantation of modular tumor endoprostheses may be a suitable treatment for bone metastases with a low complication rate and rapid improvement in function in appropriately selected patients.

【 授权许可】

   
2014 Henrichs et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Riccio AI, Wodajo FM, Malawer M: Metastatic carcinoma of the long bones. Am Fam Physician 2007, 76:1489-1494.
• [2]Sarahrudi K, Hora K, Heinz T, Millington S, Vecsei V: Treatment results of pathological fractures of the long bones: a retrospective analysis of 88 patients. Int Orthop 2006, 30:519-524.
• [3]Nathan SS, Healey JH, Mellano D, Hoang B, Lewis I, Morris CD, Athanasian EA, Boland PJ: Survival in patients operated on for pathologic fracture: implications for end-of-life orthopedic care. J Clin Oncol 2005, 23:6072-6082.
• [4]Bauer HC: Controversies in the surgical management of skeletal metastases. J Bone Joint Surg 2005, 87:608-617.
• [5]Vogl UM, Zehetgruber H, Dominkus M, Hejna M, Zielinski CC, Haitel A, Schmidinger M: Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. Br J Cancer 2006, 95(6):691-698.
• [6]Attar S, Steffner RJ, Avedian R, Hussain WM: Surgical intervention of nonvertebral osseous metastasis. Cancer Control 2012, 19:113-121.
• [7]Harvey N, Ahlmann ER, Allison DC, Wang L, Menendez LR: Endoprostheses last longer than intramedullary devices in proximal femur metastases. Clin Orthop Relat Res 2012, 470:684-691.
• [8]Wedin R, Bauer HC: Surgical treatment of skeletal metastatic lesions of the proximal femur: endoprosthesis or reconstruction nail? J Bone Joint Surg 2005, 87:1653-1657.
• [9]Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006, 12:6243s-6249s.
• [10]Durr HR, Maier M, Pfahler M, Baur A, Refior HJ: Surgical treatment of osseous metastases in patients with renal cell carcinoma. Clin Orthop Relat Res 1999, 367:283-290.
• [11]Fottner A, Szalantzy M, Wirthmann L, Stähler M, Baur-Melnyk A, Jansson V, Dürr HR: Bone metastases from renal cell carcinoma: patient survival after surgical treatment. BMC Musculoskelet Disord 2010, 11:145. BioMed Central Full Text
• [12]Bauer HC, Wedin R: Survival after surgery for spinal and extremity metastases. Prognostication in 241 patients. Acta Orthop Scand 1995, 66:143-146.
• [13]Hansen BH, Keller J, Laitinen M, Berg P, Skjeldal S, Trovik C, Nilsson J, Walloe A, Kalén A, Wedin R: The Scandinavian sarcoma group skeletal metastasis register. Survival after surgery for bone metastases in the pelvis and extremities. Acta Orthop Scand Suppl 2004, 75:11-15.
• [14]Utzschneider S, Weber P, Fottner A, Wegener B, Jansson V, Dürr HR: [Prognosis-adapted surgical management of bone metastases]. Orthopade 2009, 38(308):310-312. 314–305
• [15]Menendez LR, Ahlmann ER, Kermani C, Gotha H: Endoprosthetic reconstruction for neoplasms of the proximal femur. Clin Orthop Relat Res 2006, 450:46-51.
• [16]Plotz W, Rechl H, Burgkart R, Messmer C, Schelter R, Hipp E, Gradinger R: Limb salvage with tumor endoprostheses for malignant tumors of the knee. Clin Orthop Relat Res 2002, 405:207-215.
• [17]Gosheger G, Gebert C, Ahrens H, Streitbuerger A, Winkelmann W, Hardes J: Endoprosthetic reconstruction in 250 patients with sarcoma. Clin Orthop Relat Res 2006, 450:164-171.
• [18]Bickels J, Meller I, Henshaw RM, Malawer MM: Reconstruction of hip stability after proximal and total femur resections. Clin Orthop Relat Res 2000, 375:218-230.
• [19]Kelly CM, Wilkins RM, Eckardt JJ, Ward WG: Treatment of metastatic disease of the tibia. Clin Orthop Relat Res 2003, 415:S219-S229.
• [20]Wedin R, Bauer HC, Wersall P: Failures after operation for skeletal metastatic lesions of long bones. Clin Orthop Relat Res 1999, 358:128-139.
• [21]Hechmati G, Cure S, Gouépo A, Hoefeler H, Lorusso V, Lüftner D, Duran I, Garzon-Rodriguez C, Ashcroft J, Wei R, Ghelani P, Bahl A: Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study. J Med Econ 2013, 16(5):691-700.
• [22]Singh G, Lim CT, Jonathan TJ, Nathan SS: Evaluation of the role and cost-effectiveness of end-of-life orthopaedic interventions in cancer patients with skeletal metastases to the hip. J Palliat Care 2013, 29(2):83-90.
• [23]Ashford RU, Hanna SA, Park DH, Pollock RC, Skinner JA, Briggs TW, Cannon SR: Proximal femoral replacements for metastatic bone disease: financial implications for sarcoma units. Int Orthop 2010, 34(5):709-713.
• [24]Guest JF, Sladkevicius E, Gough N, Linch M, Grimer R: Utility values for advanced soft tissue sarcoma health States from the general public in the United kingdom. Sarcoma 2013, 2013:863056.
• [25]Ratasvuori M, Wedin R, Hansen BH, Keller J, Trovik C, Zaikova O, Bergh P, Kalen A, Laitinen M: Prognostic role of en-bloc resection and late onset of bone metastasis in patients with bone-seeking carcinomas of the kidney, breast, lung, and prostate: SSG study on 672 operated skeletal metastases. J Surg Oncol 2014, 110(4):360-365.